Comparison of Total Body Irradiation (TBI) Conditioning with Non-TBI for Autologous Stem Cell Transplantation in Newly Diagnosed or Relapsed Mature T- and NK-Cell Non-Hodgkin Lymphoma.
- Author:
Chi Hoon MAENG
1
;
Young Hyeh KO
;
Do Hoon LIM
;
Eun Suk KANG
;
Joon Young CHOI
;
Won Seog KIM
;
Seok Jin KIM
Author Information
- Publication Type:Original Article
- Keywords: T-lymphocytes; Nutural killer cells; Lymphoma; Stem cell transplantation; Whole-body irradiation
- MeSH: Disease Progression; Disease-Free Survival; Humans; Lymphoma; Lymphoma, Non-Hodgkin*; Mortality; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation*; Stem Cells*; T-Lymphocytes; Whole-Body Irradiation*
- From:Cancer Research and Treatment 2017;49(1):92-103
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: This retrospective study was conducted for comparison of survival outcomes and toxicities of autologous stem cell transplantation (ASCT) based on the use of total body irradiation (TBI) as a part of the conditioning regimen in patients with mature T- and natural killer (NK)-cell lymphomas. MATERIALS AND METHODS: Patients who underwent ASCT in the upfront or salvage setting between January 2000 and December 2013 were analyzed. Patients were dichotomized according to the TBI group (n=38) and non-TBI group (n=60) based on the type of conditioning regimen for ASCT. RESULTS: Patients with responsive disease underwent upfront ASCT (TBI, n=16; non-TBI, n=29) whereas patients with refractory disease (TBI, n=9; non-TBI, n=12) or relapsed disease (TBI, n=13; non-TBI, n=19) underwent ASCT after salvage treatment. Hematologic and non-hematologic toxicities were manageable, and the median cumulative toxicity score according to Seattle criteria was estimated as 2 (range, 0 to 7) in both groups. No significant difference in 100-day mortality was observed between the TBI (13%, 5/38) and non-TBI (12%, 12/60) groups, and most deaths were related to disease progression. There was no difference in overall and progression-free survival; however, the TBI group showed a trend of better survival in upfront and salvage ASCT than the non-TBI group. However, patients with refractory disease showed the worst outcome regardless of the use of TBI. Patients who showed complete response before ASCT showed better progression-free survival than thosewho showed partial response. CONCLUSION: TBI could be used as an effective part of conditioning for ASCT in patients with mature T- and NK-cell lymphomas.
